Association of Host Pharmacodynamic Effects with Virologic Response to Pegylated Interferon alfa-2a/Ribavirin in Chronic Hepatitis C
Association of Host Pharmacodynamic Effects with Virologic Response to Pegylated Interferon alfa-2a/Ribavirin in Chronic Hepatitis C
复制标题
DOI：
10.1002/hep.23947
复制
发表时间：
2010-12-01
期刊：
影响因子：
13.5
通讯作者：
Di Bisceglie, Adrian M.
中科院分区：
文献类型：
--
作者：
Chung, Raymond T.;Poordad, Fred F.;Di Bisceglie, Adrian M.
接受慢性丙型肝炎病毒（HCV）感染治疗的患者经常出现血细胞减少和体重减轻。我们通过评估血液学参数、体重和病毒学应答变化之间的关系，回顾性评估了聚乙二醇干扰素（PEG-IFN）α-2a和利巴韦林的药效学作用。从4个3/4期试验中汇总了接受24或48周PEG-IFN α-2a和利巴韦林治疗的患者，根据病毒学应答分类评估治疗期间血红蛋白水平、中性粒细胞计数、血小板计数和体重的最大降低（持续病毒学应答[SVR]、复发、突破和无应答者）和种族/种族在分析的1，778名患者中，超过一半是男性、非西班牙裔白人，感染HCV基因型1，基线HCV RNA > 800，000，丙氨酸转氨酶水平
Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic parameters, body weight, and virologic response Patients with HCV genotypes 1, 4, 5, or 6 receiving 24 or 48 weeks of PEG-IFN alfa-2a and ribavirin therapy were pooled from four phase 3/4 trials Maximum decreases in hemoglobin level, neutrophil count, platelet count, and weight during therapy were assessed according to virologic response category (sustained virologic response [SVR], relapse, breakthrough, and nonresponder) and race/ethnicity Of 1,778 patients analyzed, more than half were male, non-Hispanic Caucasian, and infected with HCV genotype 1, had a baseline HCV RNA >800,000, and had alanine aminotransferase levels